Manejo del Síndrome Coronario Agudo sin Elevación del ST

Manejo Inicial del Dolor Isquémico

Los pacientes con síndrome coronario agudo sin elevación del ST y dolor isquémico continuo deben recibir nitroglicerina sublingual (0,3-0,4 mg) cada 5 minutos hasta un máximo de 3 dosis, según recomiendan las guías de la American Heart Association 1, 2
Después de las 3 dosis de nitroglicerina sublingual, se debe evaluar la necesidad de administrar nitroglicerina intravenosa si el dolor persiste y no hay contraindicaciones, como sugiere la American Heart Association 1, 2
La nitroglicerina intravenosa está indicada para isquemia persistente, insuficiencia cardíaca o hipertensión, según las guías de la American Heart Association 1, 3

Contraindicaciones y Precauciones

La nitroglicerina está contraindicada en pacientes que han usado inhibidores de fosfodiesterasa (como sildenafil) en las últimas 24-48 horas, según las guías de la American Heart Association 1, 4, 3
No debe administrarse a pacientes con hipotensión (presión arterial sistólica < 90 mmHg o 30 mmHg por debajo de la línea base), bradicardia extrema (< 50 lpm) o taquicardia (> 100 lpm) en ausencia de insuficiencia cardíaca, como recomiendan las guías de la American Heart Association 5
Se debe tener precaución en pacientes con infarto de pared inferior y realizar un ECG del lado derecho para evaluar infarto del ventrículo derecho, según las guías de la American Heart Association 5

Algoritmo de Manejo del Dolor Isquémico

Administrar nitroglicerina sublingual 0,3-0,4 mg cada 5 minutos (máximo 3 dosis), como recomiendan las guías de la American Heart Association 1, 2
Si el dolor persiste después de 3 dosis sublinguales, iniciar nitroglicerina intravenosa (comenzando a 10 μg/min y aumentando 10 μg/min cada 3-5 minutos hasta respuesta), según las guías de la American Heart Association 6
Monitorizar presión arterial y frecuencia cardíaca, como sugiere la American Heart Association 4

Management of Acute Coronary Syndrome

Initial Management

The American College of Cardiology recommends IV nitroglycerin for persistent ischemic chest pain after sublingual nitroglycerin administration in hemodynamically stable patients with ACS 7, 8
IV nitroglycerin should be started at 10 μg/min and titrated upward by 10 μg/min every 3-5 minutes until pain relief or hemodynamic limits are reached 8
The American Heart Association suggests that oral beta-blockers should be initiated within the first 24 hours in hemodynamically stable patients, but IV nitroglycerin takes priority for active chest pain relief 7

Anti-Ischemic Therapy

Morphine is reserved for chest pain that is resistant to maximally tolerated anti-ischemic medications, not as the immediate next step after sublingual nitroglycerin 7, 8, 9
The appropriate dose of morphine would be 2-4 mg IV, repeated every 5-15 minutes if needed, but only after IV nitroglycerin trial 8

Contraindications and Precautions

Never give nitrates within 24 hours of sildenafil/vardenafil or 48 hours of tadalafil due to risk of severe hypotension 7, 8
Avoid nitrates if systolic BP <90 mmHg or >30 mmHg drop from baseline 8
NSAIDs other than aspirin must be discontinued as they increase MACE risk 7, 9, 10

Concurrent Therapies

Dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) is recommended 7, 8, 10
High-intensity statin therapy should be initiated within 24 hours 7
Oxygen should only be used if saturation <90% or respiratory distress 7, 8

Morphine Use in Acute Coronary Syndrome

Indication and Position in the Treatment Algorithm

Morphine is reserved for refractory moderate‑to‑severe chest pain after maximal tolerated anti‑ischemic therapy (oxygen if hypoxic, aspirin, P2Y12 loading, and sublingual or IV nitroglycerin) has failed; it is not a first‑line analgesic in ACS. 11
The recommended stepwise sequence is: (1) sublingual nitroglycerin 0.3–0.4 mg every 5 min (max 3 doses); (2) IV nitroglycerin starting at 10 µg/min and titrated upward by 10 µg/min every 3–5 min for persistent pain; (3) morphine 2–4 mg IV only if pain remains despite the above measures. 11

Dosing and Administration Protocol

Initial morphine dose: 2–4 mg IV push. 11
Repeat dosing may be given every 5–15 min as needed, with a cumulative dose up to 10 mg considered for severe refractory pain. 11

Monitoring Requirements

Continuous monitoring for respiratory depression (respiratory rate, depth, oxygen saturation) is mandatory after morphine administration. 12
Blood pressure should be checked at least every 5 min initially to detect hypotension. 11

Drug Interaction with Oral P2Y12 Inhibitors

Morphine slows gastrointestinal motility, delaying absorption and pharmacodynamic effect of oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel). This interaction is pharmacologically confirmed but its clinical relevance remains disputed in the 2025 ACC/AHA guideline. 11
Despite the interaction, the guideline advises that it should not preclude morphine use when pain is refractory, as the analgesic benefit (reducing sympathetic drive and myocardial oxygen demand) may outweigh the theoretical antiplatelet delay. 11

Contraindications and Precautions

Morphine should be withheld in the presence of: (a) respiratory depression or significant hypoxia; (b) severe hypotension (systolic BP < 90 mmHg); (c) suspected right‑ventricular infarction; (d) known morphine allergy or hypersensitivity. 11

Alternative Opioid Option

Fentanyl 25–50 µg IV (up to 100 µg) may be used as an alternative opioid with the same indications, precautions, and P2Y12 interaction concerns as morphine. 11

Evidence on Clinical Outcomes

Observational data suggest that morphine use in ACS is associated with a higher risk of in‑hospital recurrent myocardial infarction (odds ratio ≈ 1.30). However, no significant differences have been observed for all‑cause mortality, stroke, or major bleeding. The guideline notes that morphine remains recommended because it provides effective pain relief when other therapies fail. 11

Hemodynamic Stability Prior to Administration

Ensure the patient is hemodynamically stable (systolic BP ≥ 90 mmHg, no cardiogenic shock, no suspected right‑ventricular infarction) before giving morphine. 11

Morphine Use in Acute Coronary Syndrome Refractory Chest Pain

Definition of Refractory Chest Pain

Refractory chest pain requiring morphine is defined as pain that persists after three sublingual nitroglycerin doses (0.3‑0.4 mg every 5 min), not after failure of a fully titrated intravenous nitroglycerin drip. 13, 14, 15

Initial Nitroglycerin Therapy (Sublingual)

The evidence‑based first step is a trial of sublingual nitroglycerin 0.3‑0.4 mg administered every 5 minutes, up to a maximum of three doses. 13, 14, 15
After the three sublingual doses, clinicians must assess pain response before proceeding to intravenous therapy. 13, 14, 15

Intravenous Nitroglycerin Protocol

If pain persists after the sublingual trial and the patient’s blood pressure permits (SBP ≥ 90 mmHg), start IV nitroglycerin at 10 µg/min. 13
Titrate the IV infusion upward by 10 µg/min every 3–5 minutes until symptom relief or until hemodynamic limits are reached. 13
IV nitroglycerin is indicated for ongoing ischemic discomfort, uncontrolled hypertension, or pulmonary congestion. 14, 15

Morphine Indications and Administration

Morphine 2–4 mg IV is reserved for pain that persists despite sublingual nitroglycerin and an adequate trial of other anti‑ischemic therapy (e.g., beta‑blockers, IV nitroglycerin). 13, 14, 15
The guidelines explicitly state that morphine is indicated for patients whose symptoms are not relieved after three serial sublingual nitroglycerin tablets. 13
Morphine may be administered along with IV nitroglycerin when pain remains, without waiting for a fully exhausted IV nitroglycerin titration. 13
ACC/AHA guidelines (2000, 2004) emphasize that the trigger for morphine is failure of sublingual nitroglycerin, not failure of a fully titrated IV drip. 13, 14, 15
The 2000 unstable‑angina guideline adds that morphine is also appropriate when symptoms recur despite adequate anti‑ischemic therapy, which includes beta‑blockers and initiation of IV nitroglycerin. 13

Hemodynamic Contraindications (Applicable to All Therapies)

Systolic blood pressure must be ≥ 90 mmHg (or not >30 mmHg below the patient’s baseline). 13, 14, 15
Heart rate should be 50–100 bpm; severe bradycardia (< 50 bpm) or tachycardia (> 100 bpm) without heart‑failure is a contraindication. 14, 15
No phosphodiesterase‑5 inhibitor use within the prior 24 hours (48 hours for tadalafil). 14, 15
Suspected right‑ventricular infarction precludes nitroglycerin or morphine administration. 13, 14, 15

Timing of Analgesia

The 1990 ACC/AHA guideline stresses that effective analgesia (e.g., morphine) should be given promptly at the time of diagnosis and not delayed while awaiting the results of anti‑ischemic therapy. 16
Morphine provides analgesia and hemodynamic benefit by reducing sympathetic discharge, preload, and afterload. 16